Bruce J Dezube
Overview
Explore the profile of Bruce J Dezube including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
5994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yap T, Bessudo A, Hamilton E, Sachdev J, Patel M, Rodon J, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35332062
Background: Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and...
2.
Farkkila A, Gulhan D, Casado J, Jacobson C, Nguyen H, Kochupurakkal B, et al.
Nat Commun
. 2020 May;
11(1):2543.
PMID: 32424117
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
3.
Farkkila A, Gulhan D, Casado J, Jacobson C, Nguyen H, Kochupurakkal B, et al.
Nat Commun
. 2020 Mar;
11(1):1459.
PMID: 32193378
Combined PARP and immune checkpoint inhibition has yielded encouraging results in ovarian cancer, but predictive biomarkers are lacking. We performed immunogenomic profiling and highly multiplexed single-cell imaging on tumor samples...
4.
Konstantinopoulos P, Waggoner S, Vidal G, Mita M, Moroney J, Holloway R, et al.
JAMA Oncol
. 2019 Jun;
5(8):1141-1149.
PMID: 31194228
Importance: Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited. Objective: To evaluate the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib combined...
5.
Vinayak S, Tolaney S, Schwartzberg L, Mita M, McCann G, Tan A, et al.
JAMA Oncol
. 2019 Jun;
5(8):1132-1140.
PMID: 31194225
Importance: Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti-programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). Objective: To evaluate the clinical activity...
6.
Lockhart A, Bauer T, Aggarwal C, Lee C, Harvey R, Cohen R, et al.
Invest New Drugs
. 2018 May;
37(1):87-97.
PMID: 29781056
Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received...
7.
Swords R, Coutre S, Maris M, Zeidner J, Foran J, Cruz J, et al.
Blood
. 2018 Jan;
131(13):1415-1424.
PMID: 29348128
Pevonedistat (TAK-924/MLN4924) is a novel inhibitor of NEDD8-activating enzyme (NAE) with single-agent activity in relapsed/refractory acute myeloid leukemia (AML). We performed a phase 1b study of pevonedistat (PEV) with azacitidine...
8.
Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille M, et al.
Clin Lymphoma Myeloma Leuk
. 2016 Oct;
16(11):625-636.e3.
PMID: 27686689
Background: Many elderly patients with acute myeloid leukemia (AML) are considered ineligible for standard intensive induction therapy due to performance status and comorbidities. We analyzed treatment patterns and outcomes among...
9.
Bhatia S, Pavlick A, Boasberg P, Thompson J, Mulligan G, Pickard M, et al.
Invest New Drugs
. 2016 Apr;
34(4):439-49.
PMID: 27056178
Purpose The therapeutic index of proteasome inhibitors may be improved through selective inhibition of a sub-component of the ubiquitin-proteasome system, such as the NEDD8-conjugation pathway. This multicenter, phase I, dose-escalation...
10.
Noy A, Lensing S, Moore P, Gupta N, Aboulafia D, Ambinder R, et al.
Leuk Lymphoma
. 2015 Dec;
57(7):1731-4.
PMID: 26674561
No abstract available.